Cena / účtovná hodnotae spoločnosti Apellis Pharmaceuticals Inc
Aká je hodnota metriky Cena / účtovná hodnotae spoločnosti Apellis Pharmaceuticals Inc?
Hodnota metriky Cena / účtovná hodnotae spoločnosti Apellis Pharmaceuticals Inc je 27.93
Aká je definícia metriky Cena / účtovná hodnotae?
Cena / učtovná hodnota (Price to book ratio) ukazateľ vyjadruje pomer medzi hodnotou spoločnosti a book value spoločnosti, čo je hodnota čistých aktív.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Cena / účtovná hodnotae spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Apellis Pharmaceuticals Inc
Čomu sa venuje spoločnosť Apellis Pharmaceuticals Inc?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Firmy s metrikou cena / účtovná hodnotae podobnou spoločnosti Apellis Pharmaceuticals Inc
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Eidos Therapeutics Inc je 27.71
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Cauldron je 27.73
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Shakti Pumps (India) je 27.77
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Abbvie Inc je 27.83
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Dixon Technologies (India) je 27.84
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Tata Elxsi je 27.89
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Apellis Pharmaceuticals Inc je 27.93
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Adani Gas je 27.94
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Livongo Health je 27.99
- Hodnota metriky Cena / účtovná hodnotae spoločnosti SAB Events & Governance Now Media Private je 28.10
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Colonial Coal International je 28.14
- Hodnota metriky Cena / účtovná hodnotae spoločnosti BikeExchange Pty Ltd je 28.19
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Confidence Intelligence je 28.20